|
| |
QLK3-2001-00448 |
Development of highly specific enzymes for genome manipulation (EnGeM) |
| |
QLK3-2002-02132 |
Microalgae as cell factories for chemical and biochemical products (ALGINET) |
| |
QLK3-2002-01969 |
Protecting the benefits of Bt-toxins from insect resistance development by monitoring and management (ProBenBt) |
| |
QLK3-2002-01772 |
Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen) |
| |
QLK3-2002-01772 |
Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen) |
| |
QLK3-2002-02114 |
European network to develop new therapeutic strategies for Parkinson's Disease using lentiviral vector technology ((N)EUROPARK) |
| |
QLK3-2002-02038 |
Demonstration of increased yield and productivity in selected commercial organisms by strategic transformation of key genes from Aspergillus niger (ANTICO) |
| |
| animal experimentation alternatives |
| |
QLK3-2001-00407 |
Organotypic brain slice cultures as an alternative to in vivo experimentation in the study of brain repair mechanisms (ORCA) |
| |
| animal experimentation reduction |
| |
QLK3-2001-00401 |
Prevalidation of novel alternative pharma-/toxicological screening based on yeast expression technology (MULTIPLEX) |
| |
QLK3-2002-01938 |
Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA) |
| |
QLK3-2002-01980 |
Development of an immunotherapy for breast cancer based on dendritic cells by developing and comparing different types of tumour-specific immunogens (Cancer Immutherapy) |
| |
| antigen-specific immune responses |
| |
QLK3-2001-00422 |
Targeting heme-oxygenase-1 or downstream processes: A new therapeutic approach for treatment of inflammation (HO-1) |
| |
QLK3-2001-00305 |
Deoxyuridine triphosphate nucleotidohydrolase as drug target for the control of protozoal and bacterial infections (dUTPase) |
| |
QLK3-2002-02031 |
Neuropeptides for lung treatment of rare lung diseases, primary and secondary pulmonary hypertension (Neuropeotide Lung Therapy) |
| |
| anti-inflammatory effectors |
| |
QLK3-2001-00422 |
Targeting heme-oxygenase-1 or downstream processes: A new therapeutic approach for treatment of inflammation (HO-1) |
| |
QLK3-2002-02056 |
Gene mining of metagenomes for novel enzymes and therapeutics (Gemini) |
| |
| anti-proliferative action |
| |
QLK3-2002-02031 |
Neuropeptides for lung treatment of rare lung diseases, primary and secondary pulmonary hypertension (Neuropeotide Lung Therapy) |
| |
QLK3-2002-02003 |
European standard operating procedures for electrochemotherapy and electrogenetherapy (ESOPE) |
| |
QLK3-2001-00506 |
Research, selection and mechanism of action of potential therapeutic agents against Flaviviridae (Hepatitis C virus, Dengue virus, West Nile virus) (Flavitherapeutics) |
| |
QLK3-2001-00277 |
Development of novel anti-bacterials and anti-infectives that target programmed bacterial cell death (BAS anti-microbials) |
| |
QLK3-2002-01923 |
Biosensors for in situ evaluation of bioavailability of pollutants based on transcriptional regulators à la carte (BIOCARTE) |
| |
| arterioprotective therapies |
| |
QLK3-2002-01955 |
Therapeutic strategies using VEGF substitutes and gene therapies to maintain the integrity of the arterial wall (VEGF Strategies) |
| |
QLK3-2002-01955 |
Therapeutic strategies using VEGF substitutes and gene therapies to maintain the integrity of the arterial wall (VEGF Strategies) |
| |
| artificial neural networks |
| |
QLK3-2002-01938 |
Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA) |
| |
QLK3-2002-01939 |
Micro-arrays for the detection of the abundance and distribution of pathogenic protozoa, flagellated algae and diatoms (MICROPAD) |
| |
QLK3-2002-02017 |
Clearance of apoptotic cells: Discovery of autoantigens and therapy for autoimmune diseases (APOCLEAR) |
| |
QLK3-2002-01936 |
Predicting outcome and developing new therapeutic strategies for haematological stem cell transplant recipients using in vitro techniques (TRANSEUROPE) |
|
